New drug KIVU-107 enters first human tests for hard-to-treat cancers

NCT ID NCT07229313

First seen Nov 16, 2025 · Last updated May 01, 2026 · Updated 17 times

Summary

This early-stage study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells. The main goal is to find a safe dose and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kivu Trial Site

    RECRUITING

    Santa Monica, California, 90403, United States

  • Kivu Trial Site

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Kivu Trial Site

    RECRUITING

    Sydney, New South Wales, Australia

  • Kivu Trial Site

    RECRUITING

    Brisbane, Queensland, Australia

  • Kivu Trial Site

    RECRUITING

    Adelaide, South Australia, Australia

  • Kivu Trial Site

    RECRUITING

    Geelong, Victoria, Australia

Conditions

Explore the condition pages connected to this study.